Expression, prognostic value and function of LMBR1L in gastric cancer.
Summary
This study investigated the role of the LMBR1L protein in gastric cancer, revealing its significant overexpression in tumor tissues. Patients with high LMBR1L levels exhibited reduced postoperative overall and disease-free survival rates. Multivariate analyses confirmed LMBR1L expression as an independent risk factor for gastric cancer patient prognosis. Furthermore, a nomogram model incorporating LMBR1L demonstrated good predictive value for postoperative survival. In vivo experiments also indicated that LMBR1L knockdown significantly inhibits tumor growth.
Analysis
🔴 CLINIQUE : This study identifies LMBR1L as an independent prognostic biomarker for gastric cancer, correlated with poorer postoperative survival. The constructed nomogram model, incorporating LMBR1L, showed predictive value for 1-, 3-, and 5-year survival with AUCs of 0.642, 0.691, and 0.690, respectively. These findings suggest that LMBR1L could aid in risk stratification and postoperative clinical decision-making, potentially justifying later-phase clinical trials to validate its utility. Clinical impact could be seen in 3-5 years, following validation in larger cohorts. 🟢 BIOMOL : The discovery of LMBR1L as a prognostic biomarker and potential therapeutic target is significant. Protein expression was validated using immunohistochemistry and Western blot. Functional experiments, both in vitro (HGC-27 cell line with LMBR1L knockdown) and in vivo (nude mouse xenograft model), demonstrated that LMBR1L promotes gastric cancer progression. These techniques confirm the analytical validity of the observation and pave the way for investigating underlying molecular mechanisms and developing targeted therapies.